The Malignant Fibrous Histiocytoma of Soft Tissue drugs in development market research report provides comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma of Soft Tissue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malignant Fibrous Histiocytoma of Soft Tissue. Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malignant Fibrous Histiocytoma of Soft Tissue and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Malignant Fibrous Histiocytoma of Soft Tissue by ten companies/universities/institutes. The top development phase for Malignant Fibrous Histiocytoma of Soft Tissue is phase i with four drugs in that stage. The Malignant Fibrous Histiocytoma of Soft Tissue pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Malignant Fibrous Histiocytoma of Soft Tissue pipeline products market are: Hutchison MediPharma, Abbisko Therapeutics and Elixiron Immunotherapeutics.
The key targets in the Malignant Fibrous Histiocytoma of Soft Tissue pipeline products market include Macrophage Colony Stimulating Factor 1 Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Bcr-Abl Tyrosine Kinase.
The key mechanisms of action in the Malignant Fibrous Histiocytoma of Soft Tissue pipeline product include Macrophage Colony Stimulating Factor 1 Receptor Inhibitor with six drugs in Pre-Registration. The Malignant Fibrous Histiocytoma of Soft Tissue pipeline products include eight routes of administration with the top ROA being Oral and two key molecule types in the Malignant Fibrous Histiocytoma of Soft Tissue pipeline products market including Small Molecule, and Monoclonal Antibody.
Malignant Fibrous Histiocytoma of Soft Tissue overview
Malignant fibrous histiocytoma (MFH), now known as undifferentiated pleomorphic sarcoma, is a type of cancerous tumor that originates in the bone or soft tissue or other organ parts of the body. It is the most common form of soft tissue tumors generally seen in adults and very rarely in children. It is a painless mass believed to originate from primitive mesenchymal cells arising from soft tissue or bone, usually in the extremities or retroperitoneum. It can occur in any part of the body and may metastasize to lungs, lymph nodes, and bones. The etiology is still unknown, but radiation exposure is believed to be one of the common causes of this condition. Diagnosis is done by MRI and CT scan. Treatment is either surgery or radiotherapy.
For a complete picture of Malignant Fibrous Histiocytoma of Soft Tissue’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.